WFDC2 and aortic stenosis: This novel biomarker may be useful to enhance risk stratification in patients undergoing TAVI and for therapeutic decision-making in asymptomatic patients with severe AS.PerspectivesCOMPETENCY IN MEDICAL KNOWLEDGE: Higher HE4 serum levels (≥130 pmol/L) are associated with adverse clinical outcomes and treatment futility following TAVI, even in asymptomatic patients with severe AS.